179 related articles for article (PubMed ID: 24023757)
1. Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
Lloyd SM; Stott DJ; de Craen AJ; Kearney PM; Sattar N; Perry I; Packard CJ; Briggs A; Marchbank L; Comber H; Jukema JW; Westendorp RG; Trompet S; Buckley BM; Ford I
PLoS One; 2013; 8(9):e72642. PubMed ID: 24023757
[TBL] [Abstract][Full Text] [Related]
2. Homocysteine levels and treatment effect in the PROspective Study of Pravastatin in the Elderly at Risk.
Drewes YM; Poortvliet RK; Blom JW; de Ruijter W; Westendorp RG; Stott DJ; Blom HJ; Ford I; Sattar N; Wouter Jukema J; Assendelft WJ; de Craen AJ; Gussekloo J
J Am Geriatr Soc; 2014 Feb; 62(2):213-21. PubMed ID: 24447238
[TBL] [Abstract][Full Text] [Related]
3. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
[TBL] [Abstract][Full Text] [Related]
4. Blood pressure variability and cardiovascular risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
Poortvliet RK; Ford I; Lloyd SM; Sattar N; Mooijaart SP; de Craen AJ; Westendorp RG; Jukema JW; Packard CJ; Gussekloo J; de Ruijter W; Stott DJ
PLoS One; 2012; 7(12):e52438. PubMed ID: 23285043
[TBL] [Abstract][Full Text] [Related]
5. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.
Shepherd J; Blauw GJ; Murphy MB; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Meinders AE; Norrie J; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG;
Lancet; 2002 Nov; 360(9346):1623-30. PubMed ID: 12457784
[TBL] [Abstract][Full Text] [Related]
6. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
[TBL] [Abstract][Full Text] [Related]
7. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Hague W; Forder P; Simes J; Hunt D; Tonkin A;
Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
[TBL] [Abstract][Full Text] [Related]
8. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study.
Ford I; Murray H; McCowan C; Packard CJ
Circulation; 2016 Mar; 133(11):1073-80. PubMed ID: 26864092
[TBL] [Abstract][Full Text] [Related]
10. Preventing the next event in the elderly: the PROSPER perspective.
Shepherd J
Atheroscler Suppl; 2003 Dec; 4(5):17-22. PubMed ID: 14980231
[TBL] [Abstract][Full Text] [Related]
11. A prospective study of pravastatin in the elderly at risk: new hope for older persons.
Shepherd J
Am J Geriatr Cardiol; 2004; 13(3 Suppl 1):17-24. PubMed ID: 15133425
[TBL] [Abstract][Full Text] [Related]
12. Statin Use is Not Associated with Future Long-Term Care Admission: Extended Follow-Up of Two Randomised Controlled Trials.
Burton JK; Papworth R; Haig C; McCowan C; Ford I; Stott DJ; Quinn TJ
Drugs Aging; 2018 Jul; 35(7):657-663. PubMed ID: 29916140
[TBL] [Abstract][Full Text] [Related]
13. KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly.
Akao H; Polisecki E; Kajinami K; Trompet S; Robertson M; Ford I; Jukema JW; de Craen AJ; Westendorp RG; Shepherd J; Packard C; Buckley BM; Schaefer EJ
Atherosclerosis; 2012 Feb; 220(2):456-62. PubMed ID: 22192511
[TBL] [Abstract][Full Text] [Related]
14. D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease: LIPID Study.
Simes J; Robledo KP; White HD; Espinoza D; Stewart RA; Sullivan DR; Zeller T; Hague W; Nestel PJ; Glasziou PP; Keech AC; Elliott J; Blankenberg S; Tonkin AM;
Circulation; 2018 Aug; 138(7):712-723. PubMed ID: 29367425
[TBL] [Abstract][Full Text] [Related]
15. KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study.
Iakoubova OA; Robertson M; Tong CH; Rowland CM; Catanese JJ; Blauw GJ; Jukema JW; Murphy MB; Devlin JJ; Ford I; Shepherd J
Eur J Cardiovasc Prev Rehabil; 2010 Aug; 17(4):455-61. PubMed ID: 20215968
[TBL] [Abstract][Full Text] [Related]
16. ABCA1 gene variation and heart disease risk reduction in the elderly during pravastatin treatment.
Akao H; Polisecki E; Schaefer EJ; Trompet S; Robertson M; Ford I; Jukema JW; de Craen AJ; Packard C; Buckley BM; Kajinami K;
Atherosclerosis; 2014 Jul; 235(1):176-81. PubMed ID: 24854628
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study.
Hague WE; Simes J; Kirby A; Keech AC; White HD; Hunt D; Nestel PJ; Colquhoun DM; Pater H; Stewart RA; Sullivan DR; Thompson PL; West M; Glasziou PP; Tonkin AM;
Circulation; 2016 May; 133(19):1851-60. PubMed ID: 27016105
[TBL] [Abstract][Full Text] [Related]
18. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
Margolis KL; Davis BR; Baimbridge C; Ciocon JO; Cuyjet AB; Dart RA; Einhorn PT; Ford CE; Gordon D; Hartney TJ; Julian Haywood L; Holtzman J; Mathis DE; Oparil S; Probstfield JL; Simpson LM; Stokes JD; Wiegmann TB; Williamson JD;
J Clin Hypertens (Greenwich); 2013 Aug; 15(8):542-54. PubMed ID: 23889716
[TBL] [Abstract][Full Text] [Related]
20. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study.
McConnachie A; Walker A; Robertson M; Marchbank L; Peacock J; Packard CJ; Cobbe SM; Ford I
Eur Heart J; 2014 Feb; 35(5):290-8. PubMed ID: 23839541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
